NightHawk Biosciences, Inc. (NHWK)

Market Cap	9.91M
Revenue (ttm)	2.23M
Net Income (ttm)	-51.96M
Shares Out	26.08M
EPS (ttm)	-2.00
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	50,690
Open	0.351
Previous Close	0.350
Day's Range	0.351 - 0.385
52-Week Range	0.350 - 1.300
Beta	0.48
Analysts	Hold
Price Target	n/a
Earnings Date	Nov 20, 2023

About NHWK

NightHawk Biosciences, Inc., an integrated biopharmaceutical company, develops, manufactures, and commercializes medical countermeasures that combat unmet and emerging biothreats. The company develops ANTHIM (obiltoxaximab), a monoclonal antibody antitoxin for the treatment of inhalational anthrax. The company was formerly known as Heat Biologics, Inc. and changed its name to NightHawk Biosciences, Inc. in May 2022. NightHawk Biosciences, Inc. was incorporated in 2008 and is based in Morrisville, North Carolina.

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jul 24, 2013
• Employees: 77
• Stock Exchange: NYSEAMERICAN
• Ticker Symbol: NHWK

Financial Performance

In 2022, NHWK's revenue was $6.38 million, an increase of 202.12% compared to the previous year's $2.11 million. Losses were -$43.43 million, 23.8% more than in 2021.